Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 76Terminated 41Recruiting 35Active not recruiting 23Unknown 15Withdrawn 14Not yet recruiting 5Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Radiotherapy 2Lenalidomide 2Carboplatin 2tislelizumab 1irinotecan sucrosofate 1enzalutamide 1Ruthenium-106 1Radiotherapy, Intensity-Modulated 1Paclitaxel 1Melphalan 1Mannitol 1Leukocyte Count 1Folfox protocol 1Dexamethasone 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Enrolling by invitation × Dexamethasone × Clear all
NCT07210047 2025-10-07

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

HuniLife Biotechnology, Inc.

Phase 1/2 Enrolling by invitation
21 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡